Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

Halbsguth, Teresa; Nogová, Lucia; Mueller, Horst; Sieniawski, Michal; Eichenauer, Dennis A.; Schober, Thomas; Nisters-Backes, Hiltrud; Borchmann, Peter; Diehl, Volker; Engert, Andreas; Josting, Andreas

doi:10.1182/blood-2009-11-253211

Cited by 49 publications

(32 citation statements)

References 32 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They have not been included in the present discussion as outcome data on this cohort have been published previously. 7 The SHIELD study was designed to reevaluate the VEPEMB protocol devised in Italy. 9 In the Italian study, VEPEMB was investigated in 105 patients (48 with early-stage disease and 57 with advanced-stage disease).…”

Section: Discussionmentioning

confidence: 99%

“…It is important to consider the results of the SHIELD program in the context of other international efforts, including 3 trials from the GHSG 7,8,21 and 1 from the Italian group. 20 The first study from the GHSG used BACOPP.…”

Section: Discussionmentioning

confidence: 99%

“…The first, BACOPP (bleomycin, doxorubicin, cyclophosphamide, vincristine, prednisolone, and procarbazine), was a modification of the BEACOPP regimen (as BACOPP but with the addition of etoposide and with all drugs administered at higher doses) used in younger patients. 7 The second was the gemcitabinecontaining PVAG regimen (prednisone, vincristine, adriamycin, and gemcitabine). 8 In the United Kingdom, a decision was made to adopt and reassess prospectively the VEPEMB schedule (vinblastine, cyclophosphamide, prednisolone, procarbazine, etoposide, mitoxantrone, and bleomycin) developed and evaluated by the Italian Lymphoma Group, 9 as this group had the best published outcome data at that time, derived from a study of more than 100 patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study

Proctor

Wilkinson

Jones

et al. 2012

Blood

View full text Add to dashboard Cite

The SHIELD program for Hodgkin lymphoma in patients 60 years of age or older, prospectively evaluated clinical features and outcome in a large patient cohort (n ‫؍‬ 175). The central element was a phase 2 study of VEPEMB chemotherapy (n ‫؍‬ 103, median age 73 years) incorporating comorbidity assessment. A total of 72 other patients were treated off-study but registered prospectively and treated concurrently with: ABVD (n ‫؍‬ 35); CLVPP (n ‫؍‬ 19), or other (n ‫؍‬ 18). Of VEPEMB

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study

Proctor

Wilkinson

Jones

et al. 2012

Blood

View full text Add to dashboard Cite

show abstract

“…1,2 In the absence of large randomized trials in older HL patients, there is no well-established standard chemotherapy regimen and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is considered standard of care. [2][3][4][5][6] However, ABVD is associated with severe toxicity in older patients, particularly from bleomycin-induced lung toxicity (BLT). 2,[6][7][8][9] Therefore, the use of bleomycin has been questioned in older HL patients, especially in early-stage HL.…”

Section: Introductionmentioning

confidence: 99%

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Böll

Goergen

Behringer

et al. 2016

Blood

Self Cite

View full text Add to dashboard Cite

Key Points• Two cycles of ABVD or AVD were equally tolerable in older early-stage favorable HL patients.• Excessive toxicity including severe bleomycin-induced lung toxicity occurred in older HL patients receiving 4 cycles of ABVD.Doxorubicin, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) is associated with severe toxicity in older patients, particularly from bleomycin-induced lung toxicity (BLT). Therefore, using bleomycin has been questioned in older Hodgkin lymphoma (HL) patients, especially in early-stage HL. We therefore analyzed feasibility, toxicity, and efficacy of ABVD or AVD in 287 older early-stage favorable HL patients. We included patients ‡60 years of age in the German Hodgkin Study Group HD10 and HD13 trials randomized to either 2 cycles of ABVD (23ABVD; n 5 137) or AVD (23AVD; n 5 82), each followed by involved-field radiotherapy (IF-RT), with patients randomized to 43ABVD1IF-RT (n 5 68). Patients' median age was 65 years (range, 60-75) with comparable patient and disease characteristics. Grade III-IV adverse event rates were similar in patients receiving 23AVD and 23ABVD (40% and 39%, respectively), but considerably higher in patients receiving 43ABVD (65%). Similarly, BLT was rare in patients receiving 23ABVD/AVD, but occurred in 7/69 (10%) of patients randomized to 43ABVD, with 3 lethal events. In conclusion, no effects of bleomycin on toxicity rates were detectable in older patients receiving 2 cycles of chemotherapy. However, we found a high risk of severe toxicity of bleomycin in older HL patients receiving more than 2 cycles of ABVD. These trials are registered at www.clinicaltrials.gov and www.isrctn.com as #NCT00265018 (HD10) and #ISRCTN63474366 (HD13). (Blood. 2016; 127(18):2189-2192

show abstract

“…Examples of such regimens include vinblastine, cyclophosphamide, procarbazine, etoposide, mitoxantrone and bleomycin (VEPEMB) (Levis, Anselmo, Ambrosetti, et al, 2004), vincristine, doxorubicin, bleomycin, etoposide and prednisone (ODBEP) (Macpherson, Klasa, Gascoyne, et al, 2002), prednisone, vinblastine, doxorubicin and gemcitabine (PVAG) (Boll, Bredenfeld, Gorgen, et al, 2011), and bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbacine and prednisone (BACOPP) (Halbsguth, Nogova, Mueller, et al, 2010). However, randomized studies are highly recommended in this elderly heterogenous population in order to adopt any of the new regimens as standard of care compared to traditional regimens such as ABVD.…”

Section: Treatment Optionsmentioning

confidence: 99%

Treatment of Early Stage Hodgkin Lymphoma

Srour¹,

Fayad²

2012

Hodgkin's Lymphoma

View full text Add to dashboard Cite

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

Cited by 49 publications

References 32 publications

Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study

Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Treatment of Early Stage Hodgkin Lymphoma

Contact Info

Product

Resources

About